Document Detail


Statin treatment is not associated with consistent alterations in inflammatory status of carotid atherosclerotic plaques: a retrospective study in 378 patients undergoing carotid endarterectomy.
MedLine Citation:
PMID:  16809559     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND AND PURPOSE: Anti-inflammatory qualities are held partially responsible for the reduction of cardiovascular events after statin treatment. We examined the phenotype of carotid atherosclerotic plaques harvested during carotid endarterectomy in relation to the previous use of different statins prescribed in clinical practice. METHODS: Three hundred and seventy-eight patients were included. Atherosclerotic plaques were harvested, immunohistochemically stained and semiquantitively examined for the presence of macrophages (CD68), smooth muscle cells, collagen and fat. Adjacent atherosclerotic plaques were used to study protease activity and interleukin levels. Patients' demographics were recorded and blood samples were stored. RESULTS: Serum cholesterol, low-density lipoprotein, apolipoprotein B, and C-reactive protein levels were lower in patients treated with statins compared with patients without statin treatment. Atheromatous plaques were less prevalent in patients receiving statins compared with patients without statin therapy (29% versus 42%, P=0.04). An increase of CD68 positive cells was observed in patients receiving statins compared with nonstatin treatment (P=0.05). This effect was specifically related to atorvastatin treatment. In patients treated with atorvastatin, the increased amount of CD68 positive cells were not associated with increased protease activity. In contrast, a dose-dependent decrease in protease activity was shown in the atorvastatin group. Interleukin 6 expression was lower in plaques obtained from patients treated with statins (P=0.04). CONCLUSIONS: Statin use may exert pleiotropic effects on plaque phenotype. However, not the presence of macrophages but activation with subsequent protease and cytokine release may be attenuated by statin use.
Authors:
Bart A N Verhoeven; Frans L Moll; Johan A F Koekkoek; Allard C van der Wal; Dominique P V de Kleijn; Jean Paul P M de Vries; Jan H Verheijen; Evelyn Velema; Els Busser; Arjan Schoneveld; Renu Virmani; Gerard Pasterkamp
Related Documents :
22382159 - Prevalence and length of recovery of pusher syndrome based on cerebral hemispheric lesi...
21642419 - Dry pleural dissemination in non-small cell lung cancer: prognostic and diagnostic impl...
22843269 - Frontal lobe abnormalities on mrs correlate with poor letter fluency in als.
21829039 - Enhanced nitrosative and oxidative stress with decreased total antioxidant capacity in ...
21617199 - Renal transplant recipients have elevated frequencies of circulating myeloid-derived su...
16638699 - Obesity is the only independent factor associated with ultrasound-diagnosed non-alcohol...
10063739 - Early changes in esophageal motility after endoscopic variceal sclerotherapy or ligation.
9797559 - A study of the association of hla dr, dq, and complement c4 alleles with systemic lupus...
23362989 - Volume estimation in dialysis patients: the concordance of brain-type natriuretic pepti...
Publication Detail:
Type:  Journal Article     Date:  2006-06-29
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  37     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-07-25     Completed Date:  2006-08-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2054-60     Citation Subset:  IM    
Affiliation:
Department of Vascular Surgery, University Medical Centre Utrecht, Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antigens, CD / metabolism
Antigens, Differentiation, Myelomonocytic / metabolism
Atherosclerosis / drug therapy*,  metabolism,  pathology*,  surgery
Carotid Arteries / drug effects,  metabolism,  pathology
Carotid Artery Diseases / drug therapy*,  metabolism,  pathology*,  surgery
Cytokines / antagonists & inhibitors
Dose-Response Relationship, Drug
Endarterectomy, Carotid*
Heptanoic Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage,  therapeutic use*
Immunohistochemistry
Inflammation / pathology*
Macrophages / metabolism,  pathology
Peptide Hydrolases / drug effects,  metabolism
Phenotype
Pravastatin / therapeutic use
Pyrroles / therapeutic use
Retrospective Studies
Simvastatin / therapeutic use
Chemical
Reg. No./Substance:
0/Antigens, CD; 0/Antigens, Differentiation, Myelomonocytic; 0/CD68 antigen, human; 0/Cytokines; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 110862-48-1/atorvastatin; 79902-63-9/Simvastatin; 81093-37-0/Pravastatin; EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Safety and effectiveness of radioactive coil embolization of aneurysms: effects of radiation on reca...
Next Document:  Diffusion-weighted imaging in stroke attributable to patent foramen ovale: significance of concomita...